This site makes use of Javascript, please enable your web browser to allow Javascript. Thank you.

Shores to Speak on Paragraph IV Litigation at ACI Master Symposium

September 20, 2016

DC-based Antitrust partner Laura Shores will participate as a panelist in “Revisiting Reverse-Payment Settlements and Antitrust Concerns Impacting Paragraph IV Litigation” on September 20, 2016. This panel is a part of American Conference Institute’s fourth annual Paragraph IV Disputes Master Symposium.

Paragraph IV of the Drug Price Competition and Patent Term Restoration Act, commonly referred to as Hatch-Waxman, enables a company to seek approval from the US Food and Drug Administration to market a generic drug before the expiration of a patent relating to the brand name drug upon which the generic is based.

Laura’s panel will address the following topics:

  • Developing jurisprudence regarding patent settlements post-Actavis
  • What constitutes a payment
  • Differing judicial interpretations of the “Rule of Reason Test”
  • Weighing anticompetitive harm and procompetitive benefits
  • Authorized generics
  • Structuring settlements in light of developing jurisprudence
  • The resurgence of purchaser sham litigation claims
  • The impact of cGMP’s and 483s on leverage and settlements
  • Best strategies to communicate risks and rewards of settlement to clients

This ACI master symposium functions as a “meeting of the minds,” attracting preeminent patent litigators representing brand name and generic drug makers, leading in-house counsel, esteemed jurists and government representatives to discuss, analyze and interpret the latest controversies impacting Paragraph IV litigation.

» Get more information/register for this event.

Where & When

September 20, 2016 3:30pm

InterContinental Chicago Magnificent Mile

Chicago, IL